A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete understanding of potentially druggable immune mediators of disease. To advance this, we present a comprehensive multi-omic blood atlas in patients with varying COVID-19 severity and compare with influenza, sepsis and healthy volunteers. We identify immune signatures and correlates of host response. Hallmarks of disease severity revealed cells, their inflammatory mediators and networks as potential therapeutic targets, including progenitor cells and specific myeloid and lymphocyte subsets, features of the immune repertoire, acute phase response, metabolism and coagulation. Persisting immune activation involving AP-1/p38MAPK was a specific feature of COVID-19. The plasma proteome enabled sub-phenotyping into patient clusters, predictive of severity and outcome. Tensor and matrix decomposition of the overall dataset revealed feature groupings linked with disease severity and specificity. Our systems-based integrative approach and blood atlas will inform future drug development, clinical trial design and personalised medicine approaches for COVID-19.
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001007931 | 611 | ||
EGAD00001007932 | NextSeq 500 | 16 | |
EGAD00001007957 | Illumina NovaSeq 6000 | 144 | |
EGAD00001007959 | 228 | ||
EGAD00001007960 | Illumina MiSeq | 96 | |
EGAD00001007961 | Illumina MiSeq | 91 | |
EGAD00001007962 | Illumina NovaSeq 6000 | 10 | |
EGAD00001007963 | Illumina NovaSeq 6000 | 1 | |
EGAD00001007964 | Illumina NovaSeq 6000 | 10 | |
EGAD00001007965 | Illumina NovaSeq 6000 | 10 | |
EGAD00001008007 | Illumina NovaSeq 6000 | 10 | |
EGAD00001008008 | 140 | ||
EGAD00001008009 | 611 |
Publications | Citations |
---|---|
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
Cell 185: 2022 916-938.e58 |
154 |
COMBATdb: a database for the COVID-19 Multi-Omics Blood ATlas.
Nucleic Acids Res 51: 2023 D896-D905 |
2 |
Benchmarking of analytical combinations for COVID-19 outcome prediction using single-cell RNA sequencing data.
Brief Bioinform 24: 2023 bbad159 |
2 |
Atlas-scale single-cell multi-sample multi-condition data integration using scMerge2.
Nat Commun 14: 2023 4272 |
7 |
Interferon-γ couples CD8<sup>+</sup> T cell avidity and differentiation during infection.
Nat Commun 14: 2023 6727 |
5 |
Interferon response and profiling of interferon response genes in peripheral blood of vaccine-naive COVID-19 patients.
Front Immunol 14: 2023 1315602 |
0 |